🚀 VC round data is live in beta, check it out!
Jiangsu Nhwa Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiangsu Nhwa and similar public comparables like BB Biotech, Hubei Jumpcan, Dyne Therapeutics, Yili Chuannig Biotech and more.
Jiangsu Nhwa Overview
About Jiangsu Nhwa
Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in the manufacturing of APIs and dosages. The company markets its pharmaceutical products in four main categories: anesthetic drugs, such as midazolam injection and etomidate fat emulsion injection; psychiatric drugs, including risperidone tablets and related products; neurological drugs, such as gabapentin capsules; and bulk pharmaceuticals, including fenofibrate and miconazole nitrate. In addition, the company is also involved in the pharmaceuticals trading business.
Founded
2007
HQ
Employees
5.9K
Website
Sectors
Financials (FY)
EV
$3B
Jiangsu Nhwa Financials
Jiangsu Nhwa reported last fiscal year revenue of $867M and EBITDA of $201M.
In the same fiscal year, Jiangsu Nhwa generated $625M in gross profit, $201M in EBITDA, and $155M in net income.
Revenue (LTM)
Jiangsu Nhwa P&L
In the most recent fiscal year, Jiangsu Nhwa reported revenue of $867M and EBITDA of $201M.
Jiangsu Nhwa expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $867M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $625M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 72% | XXX | XXX | XXX |
| EBITDA | — | XXX | $201M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $155M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jiangsu Nhwa Stock Performance
Jiangsu Nhwa has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Jiangsu Nhwa's stock price is $3.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -2.6% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiangsu Nhwa Valuation Multiples
Jiangsu Nhwa trades at 3.2x EV/Revenue multiple, and 13.7x EV/EBITDA.
EV / Revenue (LTM)
Jiangsu Nhwa Financial Valuation Multiples
As of April 18, 2026, Jiangsu Nhwa has market cap of $3B and EV of $3B.
Equity research analysts estimate Jiangsu Nhwa's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Nhwa has a P/E ratio of 21.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 16.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.4x | XXX | XXX | XXX |
| P/E | — | XXX | 21.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 29.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiangsu Nhwa Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jiangsu Nhwa Margins & Growth Rates
Jiangsu Nhwa's revenue in the last fiscal year grew by 4%.
Jiangsu Nhwa's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Jiangsu Nhwa Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jiangsu Nhwa Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jiangsu Nhwa | XXX | XXX | XXX | XXX | XXX | XXX |
| BB Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hubei Jumpcan | XXX | XXX | XXX | XXX | XXX | XXX |
| Dyne Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Yili Chuannig Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Denali Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Nhwa M&A Activity
Jiangsu Nhwa acquired XXX companies to date.
Last acquisition by Jiangsu Nhwa was on XXXXXXXX, XXXXX. Jiangsu Nhwa acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jiangsu Nhwa
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJiangsu Nhwa Investment Activity
Jiangsu Nhwa invested in XXX companies to date.
Jiangsu Nhwa made its latest investment on XXXXXXXX, XXXXX. Jiangsu Nhwa invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jiangsu Nhwa
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiangsu Nhwa
| When was Jiangsu Nhwa founded? | Jiangsu Nhwa was founded in 2007. |
| Where is Jiangsu Nhwa headquartered? | Jiangsu Nhwa is headquartered in China. |
| How many employees does Jiangsu Nhwa have? | As of today, Jiangsu Nhwa has over 5K employees. |
| Is Jiangsu Nhwa publicly listed? | Yes, Jiangsu Nhwa is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Jiangsu Nhwa? | Jiangsu Nhwa trades under 002262 ticker. |
| When did Jiangsu Nhwa go public? | Jiangsu Nhwa went public in 2008. |
| Who are competitors of Jiangsu Nhwa? | Jiangsu Nhwa main competitors are BB Biotech, Hubei Jumpcan, Dyne Therapeutics, Yili Chuannig Biotech. |
| What is the current market cap of Jiangsu Nhwa? | Jiangsu Nhwa's current market cap is $3B. |
| What is the current revenue of Jiangsu Nhwa? | Jiangsu Nhwa's last fiscal year revenue is $867M. |
| What is the current EV/Revenue multiple of Jiangsu Nhwa? | Current revenue multiple of Jiangsu Nhwa is 3.2x. |
| Is Jiangsu Nhwa profitable? | No, Jiangsu Nhwa is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.